Engineered immune cells take aim at Hard-to-Treat cancers

NCT ID NCT05415475

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-stage trial tests a new type of cell therapy called CEA-targeted CAR-T for people with advanced colorectal, esophageal, stomach, or pancreatic cancers that have stopped responding to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize a protein called CEA found on many tumor cells, and infusing them back into the body to attack the cancer. The main goals are to check the treatment's safety and find the best dose, while also seeing if it can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CEA CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could offer a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early phase 1 trial with only 30 participants, so the results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shandong Second Provincial General Hospital

    Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.